Making You the Expert of You! (Smart Rules for Patients)
May 10, 2022
You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.
Read Article
BSR Guideline on Idiopathic Inflammatory Myopathy
May 05, 2022
The British Society of Rheumatology (BSR) has published evidence-based guidelines for idiopathic inflammatory myopathy (IIM) affecting juvenile and adult-onset disease. This rare condition has an estimated prevalence of 5-15 per 100,000 persons.
Read Article
Male vs. Female Responders (4.15.2022)
Apr 15, 2022
Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic.
Downward Effects! Real world data from 22,934 UK #RA pts
Increased Cancer Risk with Autoimmune Disorders
Mar 31, 2022
The incidence and mortality of cancer among autoimmune diseases (AID) was studied in a large Chinese cohort, demonstrating that while onset time and risks vary, there is an increased risk of malignancy in AID.
The cohort included 8,120 AID patients from a national tertiary referral
Read ArticleRheumNow Live is Coming to Town (3.11.2022)
Mar 11, 2022
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read ArticlePredicting Treatment Response in Inflammatory Muscle Disorders
MedPage Today
Feb 17, 2022
Rheumatologists looking for clues to whether their patients with certain inflammatory myopathies will improve on immunosuppressive drugs may find them in a new study appearing in Arthritis Care & Research.
Presence of dermatomyositis-specific autoantibodies, shorter time between
Read Article
CV Risk Management in Rheumatic Disease Patients
Feb 15, 2022
The European League against Rheumatism (EULAR) has developed recommendations for cardiovascular risk (CVR) management in rheumatic disease patients based on literature review and expert consensus.
These recommendations are applicable to patients with gout, vasculitis, systemic
Read ArticleHand OA and Heroes in Rheumatology (2.11.2022)
Feb 11, 2022
Interesting reports this week about dementia, who gets hand OA and a great list of women Heroes and Pillars of Rheumatology. Tune in as Dr. Jack Cush reviews the news and journal articles from this past week in RheumNow.com.
Read Article
Hold Myophenolate or Not with COVID-19 Vaccination?
Jan 13, 2022
While the American College of Rheumatology recommends holding mycophenolate (MMF) in rheumatic and musculoskeletal diseases patients (RMD) receiving COVID-19 vaccines, there is limited data on such an approach. A recent cohort study of RMD patients showed that holding MMF yielded higher antibody
Read Article
2021 Rheumatology Year in Review
Jan 08, 2022
Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.
Read Article
New Onset Rheumatic Disorders with COVID-19 Infection
Jan 05, 2022
The journal Cells has published a review of new rheumatic disorders following COVID-19 infection. Rheumatologists have infrequently noted such events and wondered what is the true incidence or range of possible manifestations.
Infection can be an infrequent trigger to immune
Read ArticleBest of 2021: Jack of All Subspecialties
Dec 31, 2021
It's great to be a rheumatologist, but boy, it's getting harder and harder. You have to be a jack of all trades. You have to be good at cardiovascular disease, osteoporosis, vaccination, inflammatory bowel disease - it just never ends. This and more, as Dr. Cush summarizes more than a dozen
Read Article
Best of 2021: High Risk Cancer Profiling with Inflammatory Myositis A recent metanalysis of studies suggest you may be able to use certain clinical factors to stratify cancer risk in patients with idiopathic inflammatory myopathies (IIMs). https://t.co/v4F3jmfnNK https://t.co/1lflsgMZtE
Links:
Dr. John Cush @RheumNow( View Tweet )
Dec 31, 2021
Tofacitinib 1st JAK Inhibitor Approved for Ankylosing Spondylitis
The FDA approved tofacitinib (Xeljanz, Xeljanz XR) for treating active ankylosing spondylitis in adults, Pfizer announced.https://t.co/NczbrBXBl7 https://t.co/l93OM86qaX
Links:
Dr. John Cush @RheumNow( View Tweet )
Dec 17, 2021
Dr. Fiorentino on cancer risk stratification and screening in myositis. Come chat at noon in the Myositis Community Hub to learn more!
#ACR21 #ACRAmbassador https://t.co/I0iQuPAuOl
Veena Katikineni @VeenaRheumMD( View Tweet )
Nov 09, 2021
Thanks Dr David Fiorentino for his talk on CA and myositis!
⬆️risk:
- DM
- >45-50yo
- males
- TIF1-gamma Ab (4.7RR of CA)
- NXP2
- low CK
- dysphagia
⬇️ risk:
- synthetase Ab
- raynaud
- ILD
- inflamm arth
🚨TIF1-gamma🚨
- ovarian CA (older, IgG2)
#ACR21 #ACRAmbassador
Vaneet K Sandhu, MD (she/her/hers) @vksandhumd( View Tweet )
Nov 09, 2021
I remember, not that long ago, inclusion body myositis evoked resignation, for pts & clinicians. A bizarre condition where standard of care was counselling/mitigation
Now there hope might be on the horizon
Exciting to see the science & a feasible target
#ACR21 ABSTL07 @RheumNow https://t.co/CYiAXIEA0Q
David Liew @drdavidliew( View Tweet )
Nov 09, 2021
Dr Preger report 9 novel aminoacyl tRNA synthetases in IIM patients. May these allow us to spare more patients biopsy? Abstr#0001 #ACR21 @RheumNow https://t.co/ikNXCEOeuj
Richard Conway @RichardPAConway( View Tweet )
Nov 08, 2021
Knowledge Bowl at #ACR21
⭐️Approximately half of patients with IIM who develop pneumomediastinum have this subtype of dermatomyositis.
➡️Amyopathic (MDA5) dermatomyositis
@RheumNow
Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Nov 08, 2021
Dr Bass on the ICI M triad: Myositis, Myocarditis, Myasthenia--> Strongly a/w morbidity & mortality
~0.4% frequency, mortality 22% when myositis alone
~Overlap (+ myasthenia or myocarditis) more common w/ combination ICI, mortality 42%
#ACR21 #ACRAmbassador https://t.co/g50tzAYhlS
Veena Katikineni @VeenaRheumMD( View Tweet )
Nov 07, 2021
If obvious dermatomyositis, you don’t need EMG for dx but may use for severity of involvement or if failing Rx or r/o steroid myopathy. For ?polymyositis ALWAYS do bx and often do EMG as broad differential #ACR21 @RheumNow https://t.co/L1xu3OuRYJ
Janet Pope @Janetbirdope( View Tweet )
Nov 07, 2021
@KatGilekMD @RichardPAConway @RheumNow @drhectorchinoy EMG/NCS can help uncover various neurological disorders including muscle dystrophies. Obviously it depends on center and expertise. Both MRI and EMG are useful and have different complementary utilities in Myositis. Many centers are not able to perform or interpret MRI reliably.
Rohit Aggarwal @docrota( View Tweet )
Nov 07, 2021
@NU_Rheum_MSK_US @RichardPAConway @drhectorchinoy @RheumNow Muscle ultrasound can be very useful but it is not ready for prime time currently to be used to do muscle biopsies. Perhaps in few years once we know how to target the muscle for biopsy.
Rohit Aggarwal @docrota( View Tweet )
Nov 07, 2021
Clinical (Peds Rheum) Pearl at #ACR21 by Dr. John Stone:
⭐️Dilated capillaries at the eyelid margin is the last cutaneous sign to resolve in inflammatory myositis!
⭐️Do not stop treatment until this sign is gone!
#ACRBest @RheumNow https://t.co/5H3Q9mTN9x
Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Nov 07, 2021
#ACR21 #Abstr0690 Great work by @didemsayginmd et al. 2016 ACR-EULAR Myositis Response Criteria concurred with patient-reported outcomes (muscle disease activity, strength, pain, fatigue, physical function, quality of life and physical activity) @RheumNow https://t.co/IV3mAXKhbt https://t.co/GWC6IDcJSm
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Nov 07, 2021
Recent Blogs
A Winning Season*
Sep 09, 2015
Winning is everything – in football and in medicine. Rheumatologists have achieved many successes but still struggle to win against a handful of rheumatic foes. This retrospective examines past wins and losses and helps us to look ahead to a new season.
Read PostFeatured Video
